- Home
- RBOT vs EQ Comparison
RBOT vs EQ Comparison
Compare RBOT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- EQ
- Stock Information
- Founded
- RBOT 2014
- EQ 2017
- Country
- RBOT United States
- EQ United States
- Employees
- RBOT N/A
- EQ N/A
- Industry
- RBOT Medical Specialities
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- EQ Health Care
- Exchange
- RBOT Nasdaq
- EQ Nasdaq
- Market Cap
- RBOT 61.4M
- EQ 67.9M
- IPO Year
- RBOT N/A
- EQ 2018
- Fundamental
- Price
- RBOT $6.34
- EQ $1.57
- Analyst Decision
- RBOT Hold
- EQ Hold
- Analyst Count
- RBOT 1
- EQ 2
- Target Price
- RBOT $7.00
- EQ $1.00
- AVG Volume (30 Days)
- RBOT 34.4K
- EQ 2.6M
- Earning Date
- RBOT 11-11-2025
- EQ 11-12-2025
- Dividend Yield
- RBOT N/A
- EQ N/A
- EPS Growth
- RBOT N/A
- EQ N/A
- EPS
- RBOT N/A
- EQ N/A
- Revenue
- RBOT N/A
- EQ $16,553,000.00
- Revenue This Year
- RBOT N/A
- EQ N/A
- Revenue Next Year
- RBOT N/A
- EQ N/A
- P/E Ratio
- RBOT N/A
- EQ N/A
- Revenue Growth
- RBOT N/A
- EQ N/A
- 52 Week Low
- RBOT $5.00
- EQ $0.27
- 52 Week High
- RBOT $19.00
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- RBOT 46.32
- EQ 50.86
- Support Level
- RBOT $5.58
- EQ $1.78
- Resistance Level
- RBOT $5.99
- EQ $2.02
- Average True Range (ATR)
- RBOT 0.39
- EQ 0.25
- MACD
- RBOT 0.14
- EQ -0.08
- Stochastic Oscillator
- RBOT 80.07
- EQ 6.47
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.